VISEN Pharmaceuticals' H1 Loss Widens 41%

MT Newswires Live

Aug 28

VISEN Pharmaceuticals (HKG:2561) reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.

Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.

It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.

In July, the company partnered with Anhui Anke Biotechnology (SHE:300009) to jointly promote the drug in specific regions of China.

Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562070730"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562070730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562070730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562070730","market":"us","top_or_hot":-1,"title":"VISEN Pharmaceuticals' H1 Loss Widens 41%","media":"MT Newswires Live","content":"<html><body><p> VISEN Pharmaceuticals (HKG:2561) reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.</p><p>Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.</p><p>It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.</p><p>In July, the company partnered with <a href=\"https://laohu8.com/S/300009\">Anhui Anke Biotechnology</a> (SHE:300009) to jointly promote the drug in specific regions of China.</p><p>Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharmaceuticals' H1 Loss Widens 41%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharmaceuticals' H1 Loss Widens 41%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-28 14:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> VISEN Pharmaceuticals (HKG:2561) reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.</p><p>Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.</p><p>It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.</p><p>In July, the company partnered with <a href=\"https://laohu8.com/S/300009\">Anhui Anke Biotechnology</a> (SHE:300009) to jointly promote the drug in specific regions of China.</p><p>Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300009","symbol_name":"安科生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562070730","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562070730","pubTimestamp":1756360959,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"VISEN Pharmaceuticals  reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.In July, the company partnered with Anhui Anke Biotechnology  to jointly promote the drug in specific regions of China.Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300009":"安科生物","BK0239":"医药制造","BK0042":"基因检测","BK0070":"员工持股","BK1161":"生物科技","02561":"维升药业-B","BK0060":"抗癌"},"translate_title":"维森制药上半年亏损扩大41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300009":0.9,"02561":0.9},"content_text":"VISEN Pharmaceuticals (HKG:2561) reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.In July, the company partnered with Anhui Anke Biotechnology (SHE:300009) to jointly promote the drug in specific regions of China.Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}